https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan
0
0
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) - Novartis
10/2/23 at 6:25am
Organization
Novartis.com
58 words
0
Comments
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
You are the first to view
Create an account or login to join the discussion